PDF
Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years — United States, March 29, 2022–July 10, 2022
Organization: United States Centers for Disease Control (CDC)Published: 2022
"Among persons aged ≥50 years who reported homologous mRNA COVID-19 vaccination, injection site and systemic reactions were less frequent after a second booster dose than after the first booster dose. Ninety-five percent of 8,515 events reported to the Vaccine Adverse Event Reporting System were nonserious." - Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years — United States, March 29, 2022–July 10, 2022
Additional Authors: Phillip G. Blanc, John R. Su, Brandon Hugueley, Casey Parker, Tanya R. Myers, Julianne Gee, Tom T. Shimabukuro, David K. Shay
Resource Group:
Evidence
Product Type: Report
Vaccine Safety
Sub Topics: Vaccine Safety and Development
Adverse Events Following Immunization (AEFI)
Monitoring and Surveillance
Outbreaks and Pandemics
COVID-19
Specific Populations
Adults
Seniors
Product Type: Report
Category:
Vaccine Safety and Development,Vaccine Safety,Sub Topics: Vaccine Safety and Development,Adverse Events Following Immunization (AEFI),Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19,Specific Populations,Adults,Seniors Vaccine Safety and DevelopmentVaccine Safety
Sub Topics: Vaccine Safety and Development
Adverse Events Following Immunization (AEFI)
Monitoring and Surveillance
Outbreaks and Pandemics
COVID-19
Specific Populations
Adults
Seniors
Language:
English
Link
AudioResource Rating Breakdown
Ratings submitted by CANVax users for this resource are tallied to provide an average resource rating per category.
0 Comments
Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.
All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.
You must login or register before you can submit a comment.